Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Adamis Pharmaceuticals Corp    ADMP

ADAMIS PHARMACEUTICALS CORP (ADMP)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/18 04:00:00 pm
2.88 USD   --.--%
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

ADAMIS PHARMACEUTICALS CORP : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/10/2018 | 04:19pm EST

Item 2.02 Results of Operations and Financial Conditions

On August 10, 2018, Adamis Pharmaceuticals Corporation (the "Company") issued a press release announcing certain financial information for the quarter ended June 30, 2018. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished in this Form 8-K and the press release attached as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits




(d) Exhibits.


Exhibit No. Exhibit Description

99.1 Press release dated August 10, 2018

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ADAMIS PHARMACEUTICALS COR
01/18ADAMIS PHARMACEUTICALS CORP : Other Events (form 8-K)
AQ
01/17ADAMIS PHARMACEUTICALS : ' Commercial Partner Launches SYMJEPI in the US
AQ
01/17ADAMIS PHARMACEUTICALS : Commercial Partner Launches SYMJEPI (epinephrine) in th..
AQ
01/16Adamis' Commercial Partner Launches SYMJEPI™ (epinephrine) in the US
GL
2018Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Naloxone P..
GL
2018ADAMIS PHARMACEUTICALS : Submits New Drug Application to FDA for Its Tadalafil S..
AQ
2018Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Tadalafil ..
GL
2018ADAMIS PHARMACEUTICALS CORP : Other Events (form 8-K)
AQ
2018ADAMIS PHARMACEUTICALS : Provides Update on the U.S. Launch of SYMJEPI
AQ
2018Adamis Pharmaceuticals Provides Update on the U.S. Launch of SYMJEPI
GL
More news
Financials ($)
Sales 2018 16,4 M
EBIT 2018 -35,0 M
Net income 2018 -35,0 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 8,31x
Capi. / Sales 2019 4,90x
Capitalization 136 M
Chart ADAMIS PHARMACEUTICALS CORP
Duration : Period :
Adamis Pharmaceuticals Corp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS COR
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 7,00 $
Spread / Average Target 143%
EPS Revisions
Managers
NameTitle
Dennis J. Carlo President, Chief Executive Officer & Director
Richard C. Williams Chairman
Karen K. Daniels Vice President-Operations
Robert O. Hopkins Chief Financial Officer, Secretary & VP-Finance
Thomas H. Moll Vice President-Research
Sector and Competitors
1st jan.Capitalization (M$)
ADAMIS PHARMACEUTICALS CORP28.00%136
JOHNSON & JOHNSON0.03%350 508
PFIZER-2.70%246 674
NOVARTIS5.66%227 840
ROCHE HOLDING LTD.6.16%223 498
MERCK AND COMPANY-0.71%197 291